COMBINE 1, a 52-week trial comparing once-weekly IcoSema with insulin icodec in about 1300 patients, and COMBINE 2, comparing IcoSema with semaglutide in about 700 patients, ...

Diabetes patients who are sick of daily insulin shots may soon only have to inject themselves once a week. A year-long phase 3 clinical trial has shown that a weekly form of the hormone is just as ...

The insulin isodec molecule is a modified version of human insulin with a longer half-life of about 7 days. It has three amino acid changes that make it more stable, reduce its breakdown by ...

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to ...

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to research from ...

The COMBINE clinical development program also includes the COMBINE 1 trial (ClinicalTrials.gov Identifier: NCT05352815), which is comparing IcoSema with insulin icodec, and the COMBINE 2 trial ...

Once-weekly basal insulin icodec achieved superior blood sugar reduction1 (measured by a change in HbA1c) and superior Time in Range2 (time spent within recommended blood sugar range), ...

MADRID — Novo Nordisk's investigational once-weekly combination of insulin icodec plus semaglutide (IcoSema) could benefit people with type 2 diabetes who don't reach target glycemic goals with ...

Novo Nordisk A/S NVO announced positive top-line results from its late-stage COMBINE 3 study evaluating once-weekly IcoSema in 679 people with type II diabetes inadequately controlled on daily ...

Most types of insulin therapy, an important part of diabetes treatment for many people, are given as daily injections to help manage blood sugar levels. Now, the maker of a once-weekly insulin ...

The committee’s discussions focused on the safety and efficacy of insulin icodec, specifically in people with type 1 diabetes. The advisers were asked to answer a question of, based on the ...